|Bid||87.00 x 800|
|Ask||90.50 x 4000|
|Day's Range||84.60 - 87.88|
|52 Week Range||77.50 - 125.86|
|Beta (3Y Monthly)||1.79|
|PE Ratio (TTM)||18.30|
|Earnings Date||Jan 24, 2019 - Jan 28, 2019|
|Forward Dividend & Yield||4.28 (4.74%)|
|1y Target Est||100.33|
In a turbulent year for Gilead Sciences (NASDAQ:GILD), the company recently generated headlines that will hopefully turn things around for GILD stock. Over the weekend, insider information pegged Roche Holdings (OTCMKTS:RHHBY) executive Daniel O’Day as its new CEO. O’Day is no stranger to the industry, having served as Roche Pharmaceuticals’ chief executive since June 3, 2016.
AbbVie (ABBV) expects Humira to report revenue of close to $6.3 billion in international markets in 2018. AbbVie reported Humira sales worth $1.58 billion in international markets in the third quarter, YoY (year-over-year) rises of 1.8% on a reported basis and 4.2% on an operational basis.
In the third quarter, AbbVie (ABBV) reported SG&A (selling, general, and administrative) expenses of $1.57 billion, a YoY (year-over-year) rise of 8.77%. However, its adjusted SG&A as a percentage of its total revenue was 19.1% in the third quarter, a YoY improvement of 170 basis points. According to AbbVie’s third-quarter earnings conference call, the company benefited from improved operational efficiencies and sales leverage in the quarter.
On its third-quarter earnings conference call, AbbVie (ABBV) said that it expected its gross margin ratio for 2018 to be more than 80.5% and its adjusted operating margin to be close to 45%. In the third quarter, AbbVie reported an adjusted gross margin of 81.7%, a YoY (year-over-year) rise of 90 basis points. It expects a further positive impact of 170–180 basis points on its gross margin in 2019 due to the royalty termination.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
On its third-quarter earnings conference call, AbbVie (ABBV) raised its adjusted EPS guidance for 2018 from its previous projection of $7.76–$7.86 to $7.90–$7.92. The revised estimate implies a YoY (year-over-year) rise of 41.3% considering the midpoint of the guidance range. As per the company’s third-quarter earnings conference call, AbbVie expects its adjusted fourth-quarter EPS to be in the range of $1.89–$1.91 excluding a $0.26 impact of noncash amortization and other items.
On its third-quarter earnings conference call, AbbVie (ABBV) raised its net revenue guidance for 2018 from its previous projection of $32.5 billion to $32.7 billion. The company also raised its forecast for YoY (year-over-year) operational revenue growth in 2018 from 14.5% to 15.0%. As per AbbVie’s third-quarter earnings conference call, the company expects a favorable revenue impact of less than 1% due to foreign currency fluctuations in 2018.
The company saw a rise of 17.53% in its share price from $80.21 on November 1 to $94.27 on November 30. Thereafter, AbbVie saw a 3.95% fall in its share price from November 30 to December 5. On November 30, AbbVie issued a press release announcing agreements that granted Pfizer (PFE) a nonexclusive global license related to Humira’s intellectual property.
Critics of high drug prices are launching a new line of attack against manufacturers of the medicines, faulting the firms for using savings from the tax overhaul to buy back shares rather than lower prices. The attacks began in October, when more than a dozen Democrats in the House of Representatives sent letters to five big pharmaceutical companies saying they had benefited from recent tax cuts but kept charging high prices. The letters singled out certain drugs whose list prices had increased and asked their manufacturers for details about price changes and the costs of research and advertising.
In the last five years, AbbVie (NYSE:ABBV) stock is up 76%, which is impressive. Coming into today, AbbVie is down 5% in a year. The fundamentals, although very strong, are under attack from headlines about tariff wars especially between the United States and China.
Here's a roundup of top developments in the biotech space over the past 48 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 4) Johnson & Johnson (NYSE: JNJ ) Eli Lilly And Co (NYSE: ...
AbbVie Inc said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee. The committee's recommendations were based on shorter overall survival in the Rova-T arm, compared with the topotecan control arm, the company said. AbbVie acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as the company aimed to enter the broad and lucrative arena of solid tumors and lessen dependence on its arthritis treatment Humira, the world's top selling drug.
While a course of treatment once came close to $100,000, new drugs have emerged to bring the price tag way down.
- Independent Data Monitoring Committee responsible for ongoing review of study data recommended enrollment be stopped NORTH CHICAGO, Ill. , Dec. 5, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based ...